Analyst Price Targets — SION
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 3:11 pm | Brian Abrahams | RBC Capital | $5.00 | $4.08 | TheFly | Sionna Therapeutics upgraded to Sector Perform at RBC after 90% pullback |
| August 10, 2026 2:35 pm | — | Wedbush | $5.00 | $4.06 | TheFly | Wedbush downgrades Sionna Therapeutics to Neutral following trial setback |
| August 10, 2026 1:24 pm | — | Stifel Nicolaus | $7.00 | $4.09 | TheFly | Sionna Therapeutics downgraded to Hold from Buy at Stifel |
| August 7, 2026 11:41 am | — | Guggenheim | $60.00 | $49.61 | TheFly | Sionna Therapeutics price target raised to $60 from $50 at Guggenheim |
| August 6, 2026 2:24 pm | Chris Raymond | Raymond James | $59.00 | $50.02 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $59 at Raymond James |
| May 18, 2026 10:45 am | Paul Matteis | Stifel Nicolaus | $55.00 | $40.22 | TheFly | Sionna Therapeutics price target raised to $55 from $44 at Stifel |
| March 2, 2026 4:46 pm | Yatin Suneja | Guggenheim | $50.00 | $34.40 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $50 at Guggenheim following FY25 earnings report |
| January 7, 2026 12:09 pm | Kambiz Yazdi | BTIG | $58.00 | $37.22 | TheFly | Sionna Therapeutics price target raised to $58 from $50 at BTIG |
| January 5, 2026 11:24 am | Chris Raymond | Raymond James | $53.00 | $39.21 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $53 at Raymond James |
| December 1, 2025 10:37 am | — | RBC Capital | $24.00 | $43.57 | TheFly | Sionna downgraded to Underperform from Sector Perform at RBC Capital |
Latest News for SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sionna Therapeutics (SION) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have any information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SION.
U.S. House Trading
No House trades found for SION.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.